➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Mallinckrodt
Moodys
Express Scripts

Last Updated: August 3, 2021

DrugPatentWatch Database Preview

CELEBREX Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Celebrex, and when can generic versions of Celebrex launch?

Celebrex is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in CELEBREX is celecoxib. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Celebrex

A generic version of CELEBREX was approved as celecoxib by MYLAN on May 30th, 2014.

  Try it Free

Paragraph IV (Patent) Challenges for CELEBREX
Tradename Dosage Ingredient NDA Submissiondate
CELEBREX CAPSULE;ORAL celecoxib 020998 2008-03-21

US Patents and Regulatory Information for CELEBREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-004 Dec 15, 2006 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CELEBREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-003 Aug 29, 2002 ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-004 Dec 15, 2006 ⤷  Try it Free ⤷  Try it Free
Upjohn CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for CELEBREX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0731795 2009C/009 Belgium ⤷  Try it Free PRODUCT NAME: MAVACOXIB; REGISTRATION NO/DATE: EU/0/08/084/001 20080911
0731795 SZ 4/2009 Austria ⤷  Try it Free PRODUCT NAME: MAVACOXIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES
0731795 91538 Luxembourg ⤷  Try it Free 91538, EXPIRES: 20191114
0731795 300380 Netherlands ⤷  Try it Free ZOETIS SERVICES LLC
0731795 09C0007 France ⤷  Try it Free PRODUCT NAME: MAVACOXIB; REGISTRATION NO/DATE: EU/2/08/084/001 20080909
0731795 SPC/GB09/010 United Kingdom ⤷  Try it Free PRODUCT NAME: MAVACOXIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/2/08/084/001 20080909; UK EU/2/08/084/002 20080909; UK EU/2/08/084/003 20080909; UK EU/2/08/084/004 20080909; UK EU/2/08/084/005 20080909
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Mallinckrodt
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.